Sanofi Holds Its Ground On Genzyme Bid
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.